ACADIA Pharmaceuticals In... (ACAD)
Company Description
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders.
The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.
It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's.
ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.

Country | United States |
IPO Date | May 27, 2004 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 653 |
CEO | Catherine E. Owen Adams |
Contact Details
Address: 12830 El Camino Real San Diego, California United States | |
Website | https://www.acadia-pharm.com |
Stock Details
Ticker Symbol | ACAD |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001070494 |
CUSIP Number | 004225108 |
ISIN Number | US0042251084 |
Employer ID | 06-1376651 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Catherine E. Owen Adams | Chief Executive Officer & Director |
Jennifer J. Rhodes J.D. | Chief Legal Officer & Secretary |
Mark C. Schneyer | Executive Vice President & Chief Financial Officer |
Rob Ackles | Chief People Officer |
Dr. Elizabeth H.Z. Thompson Ph.D. | Head of Research & Development |
Dr. Kevin R. Oliver Ph.D. | Chief Business Officer |
James K. Kihara | Senior Vice President of Finance |
Stephen R. Davis J.D. | Consultant |
Thomas Andrew Garner | Chief Commercial Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 26, 2025 | 4 | Filing |
Mar 26, 2025 | 4 | Filing |
Mar 26, 2025 | 4 | Filing |
Mar 26, 2025 | 4 | Filing |
Mar 26, 2025 | 4 | Filing |
Mar 06, 2025 | 4 | Filing |
Feb 27, 2025 | 10-K | Annual Report |
Feb 26, 2025 | 8-K | Current Report |
Feb 25, 2025 | 4 | Filing |
Feb 25, 2025 | 4 | Filing |